Ariana Pelosci

Lifileucel, a tumor infiltrating therapy, could be the best treatment for heavily pretreated patients with advanced melanoma, with investigators at Atlantic Health System examining this treatment modality in clinical trials.

UV1 has received fast track designation from the FDA for the use in unresectable or metastatic melanoma.

Patients with hormone receptor–positive, ERBB2-negative advanced breast cancer experienced significant anti-tumor activity when treated with fulvestrant and palbociclib but did not see an improvement in progression-free survival compared with letrozole and palbociclib .

The FDA granted priority review to a new drug application for parsaclisib in patients with mantle cell lymphoma and other non-Hodgkin lymphomas.

For Pancreatic Cancer Awareness Month, CancerNetwork® spoke with Allyson Ocean, MD, about how family members of patients with pancreatic cancer should seek genetic testing to determine if they are predisposed to pancreatic cancer.

On or after week 5 of treatment with chemotherapy, trilaciclib reduced the need for supportive care therapies in patients with extensive-stage small-cell lung cancer.

Patients treated with eryaspase for second line advanced pancreatic cancer did not meet the primary end point of overall survival in the TRYbeCA-1 trial.

The AVENIO Tumor Tissue Comprehensive Genomic Profiling Kit could allow for more accessible genetic testing and result in more personalized treatments.

Although canakinumab, an investigational interleukin-1β inhibitor, plus pembrolizumab did not meet the primary end points for locally advanced metastatic non–small cell lung cancer in the CANOPY-1 trial, it could have potential in certain patient subgroups.

Patients receiving trastuzumab for HER2-positive breast cancer on the phase 3 HERA trial did not have an increased risk of cardiotoxicity from radiation therapy.

Stereotactic body radiotherapy added to standard of care treatment resulted in better progression-free survival for those with oligoprogressive non–small cell lung cancer.

The interim results of a phase 1b/2 trial showed that patients with soft tissue sarcoma and lung metastases who were treated with annamycin experienced positive clinical activity.

A phase 2 trial examining the use of small molecule immunomodulator EC-18 in patients with head and neck cancer experiencing chemoradiation-induced oral mucositis met its primary and secondary end points.

The FDA issued a complete response letter to the company responsible for developing narsoplimab because of the inability to estimate treatment effects on patients receiving hematopoietic stem cell transplant–associated thrombotic microangiopathy.

Patients with high-risk smoldering myeloma who were treated with carfilzomib, lenalidomide, and dexamethasone and lenalidomide maintenance experienced an improvement in minimal residual disease–negative complete response and could have delayed end-organ disease.

The FDA approved atezolizumab for treatment of stage II to IIIA non–small cell lung cancer following resection and platinum-based chemotherapy.

The addition of temozolomide to vincristine and irinotecan appears to be a new standard of care for adult and pediatric patients with relapsed/refractory rhabdomyosarcoma, according to the European Paediatric Soft Tissue Sarcoma Group.

Investigators identified a correlation between financial toxicity significant differences in mental and physical quality of life, and patient satisfaction with breast reconstruction among patients with breast cancer.

Patients with colorectal liver metastases who were treated with transarterial Yttrium-90 radioembolization plus second-line chemotherapy experienced a long-term survival benefit.

Patients with small cell lung cancer who failed first-line treatment within 6 months were examined for efficacy of anlotinib plus chemotherapy in a phase 2 trial whose results were presented at the 2021 ESMO Congress.

Ibrutinib for treating patients with chronic lymphocytic leukemia increased the risk of atrial fibrillation, bleeding, and heart failure in results of a cohort study.

An interim analysis indicated that dalpiciclib plus pyrotinib yielded promising results in patients with HER2-positive advanced stage breast cancer.

Andrew Armstrong, MD, MSc, spoke about key findings, patient crossover, and takeaways from the ARCHES trial for metastatic hormone-sensitive prostate cancer.

Men with metastatic hormone-sensitive prostate cancer who were treated with enzalutamide plus androgen deprivation therapy experienced an improved, long-lasting overall survival compared with those who received placebo.

Patients who were treated with ramucirumab plus gemcitabine experienced improved overall survival compared with patients treated with gemcitabine plus placebo.

Patients with previously untreated metastatic uveal melanoma who also harbored HLA-A*02:01 and were treated with tebentafusp experienced a longer overall survival compared with the control group of a phase 3 clinical trial.

Adding venetoclax to cladribine, high-dose cytarabine, and idarubicin appears to yield high rates of minimal residual disease negativity and promising survival in patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.

Patients with recurrent or metastatic cervical cancer treated with cemiplimab experienced an improved overall survival, progression-free survival, and overall response rate, leading to priority review from the FDA.

An association was identified between second-line clinical trial participation for patients with metastatic non–small cell lung cancer and a mean cost savings of $6663 for health care payers.

Patients with muscle-invasive bladder cancer treated with gemcitabine and split-dose cisplatin plus pembrolizumab experienced improved pathological downstaging.